One of oncology's most persistent puzzles is how MYC — the transcription factor gone rogue in virtually every human tumor — can simultaneously damage DNA and protect cells from that same damage. New mechanistic evidence adds a critical piece to that contradiction, with implications for how cancer cells evade chemotherapy and how that resistance might finally be disrupted.
Researchers publishing in Genes & Development identify a non-transcriptional function for MYC specifically tied to a post-translational modification: phosphorylation at serine 62 (pS62-MYC). This modified form of the protein was found to localize directly to DNA double-strand break sites — among the most lethal forms of genomic damage — where it physically interacts with two central DNA repair proteins, BRCA1 and RAD51. Both are core components of homologous recombination repair, a high-fidelity pathway particularly active in dividing cells. Proteomic interactome profiling confirmed that pS62-MYC maintains conserved associations with the broader DNA damage response machinery, lending mechanistic depth to prior correlative observations. Cells with disrupted pS62 signaling showed impaired repair efficiency and reduced survival under genotoxic stress.
This finding reframes MYC's genoprotective role as switch-like and modification-dependent rather than constitutive. That distinction matters clinically: most MYC-targeting strategies have struggled because MYC is broadly essential in normal tissues. If pS62-MYC specifically drives repair in tumor cells exposed to DNA-damaging therapies — chemotherapy, radiation, PARP inhibitors — then selective disruption of this phosphorylation event could sensitize cancers to existing treatments without systemic MYC suppression. The serine 62 site is already regulated by the RAS-ERK pathway, which is itself hyperactivated in many MYC-amplified tumors, adding potential therapeutic synergy. This work is mechanistic and cell-based, so causal validation in animal models and human tumor specimens will be essential before translational claims can be made. Nevertheless, the specificity and novelty of the pS62 mechanism earns it consideration as a genuinely promising therapeutic axis.